US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Dopamine transporter releasing agent
pharma · Obese · Hyperlipemia
Suzhou Ribo Life
Suzhou Ribo Life Science Co.
Suzhou Ribo Life drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Beijing, CN HQ
2007 Founded
32 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Beijing, CN
- Founded
- 2007
- Employees
- 32
- Programs
- 4
- Drugs
- 7
- Patents
- 0
Suzhou Ribo Life pipeline
Portfolio lens on 7 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Suzhou Ribo Life drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
aumolertinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Suzhou Ribo Life's portfolio. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
Development asset linked to Suzhou Ribo Life in public FDA and regional records.
-
Development asset linked to Suzhou Ribo Life in public FDA and regional records.
-
Development asset linked to Suzhou Ribo Life in public FDA and regional records.
-
Development asset linked to Suzhou Ribo Life in public FDA and regional records.
-
Development asset linked to Suzhou Ribo Life in public FDA and regional records.